PolyActiva is an Australian-based biotechnology company that has developed a platform technology to deliver drugs to specific sites in the body. The polymeric prodrugs can take various forms, including rod-shaped implants, injectable gels and topical films and the rate of drug delivery can be controlled for up to 12 months.
The technology enables products with high dose loads, which means sufficient drug can be carried in products of a very small size and still deliver therapeutic daily doses to the therapeutic site over extended periods. All of the products are designed to biodegrade after the treatment period, leaving no residue. As a consequence, PolyActiva's delivery technology is very well suited to drug delivery at sites of the body that have limited volumes (e.g. the eye).
With the PolyActiva technology, exceptional zero-order release profiles are achieved over treatment periods ranging from 1 to 12 months.
PolyActiva has secured a world-class team of more than 10 staff that provide the core chemistry and development capabilities. We have also established solid relationships with key research service providers, who provide capabilities in pharmaceutical chemistry, polymer chemistry, ophthalmology and commercialisation.
The technology enables products with high dose loads, which means sufficient drug can be carried in products of a very small size and still deliver therapeutic daily doses to the therapeutic site over extended periods. All of the products are designed to biodegrade after the treatment period, leaving no residue. As a consequence, PolyActiva's delivery technology is very well suited to drug delivery at sites of the body that have limited volumes (e.g. the eye).
With the PolyActiva technology, exceptional zero-order release profiles are achieved over treatment periods ranging from 1 to 12 months.
PolyActiva has secured a world-class team of more than 10 staff that provide the core chemistry and development capabilities. We have also established solid relationships with key research service providers, who provide capabilities in pharmaceutical chemistry, polymer chemistry, ophthalmology and commercialisation.
Location: Australia, Victoria, Melbourne
Employees: 11-50
Total raised: $49.52M
Founded date: 2010
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.05.2025 | Series C | $40M | - |
| 19.02.2013 | Series B | $9.52M | - |
Mentions in press and media 3
| Date | Title | Description |
| 30.05.2025 | PolyActiva Secures $40M in Series C Financing to Advance PREZIA™ Platform Technology and Drive Innovation in Sustained Ocular Drug Delivery | MELBOURNE, AUSTRALIA – 30 May 2025– PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced it secured AUD $40 million in Se... |
| 19.02.2013 | PolyActiva Raises AUD$9.2M in Series B Financing | PolyActiva, a Melbourne, Australia-based biotechnology company, raised AUD $9.2m in Series B financing. Backers included the Medical Research Commercialisation Fund (MRCF) and Brandon Biosciences Fund 1 (BBF1) (both managed by Brandon Capit... |
| 19.02.2013 | PolyActiva Raises AUD$9.2M in Series B | MELBOURNE, AUSTRALIA, PolyActiva announced today that it has raised AUD $9.2 Million in a Series B financing round from a consortium of investors. >> Click here for more funding data on PolyActiva >> To export PolyActiva fun... |